Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tamm, M.
Right arrow Articles by Cathomas, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tamm, M.
Right arrow Articles by Cathomas, G.
(Chest. 2001;119:838-843.)
© 2001 American College of Chest Physicians

Pulmonary Cytomegalovirus Infection in Immunocompromised Patients*

Michael Tamm, MD; Peter Traenkle, MD; Bruno Grilli, MIAC; Markus Solèr, MD; Chris T. Bolliger, MD, FCCP; Peter Dalquen, MD and Gieri Cathomas, MD

* From the Division of Pneumology (Drs. Tamm, Traenkle, Soler, and Bolliger), Department of Internal Medicine, and Institute of Pathology (Mr. Grilli and Drs. Dalquen and Cathomas), University Hospital Basel, Basel, Switzerland.

Correspondence to: Michael Tamm, MD, Division of Pneumology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland; e-mail: mtamm{at}uhbs.ch

Background: Cytomegalovirus (CMV) infection and CMV disease are frequent complications in immunocompromised patients. In this study, the incidence of pulmonary CMV infection was analyzed in different groups of immunocompromised patients and the diagnostic value of immunostaining with anti-CMV antibodies in BAL cells was evaluated in regard to the diagnosis of CMV pneumonitis.

Methods: Five hundred eighty consecutive BAL procedures were analyzed prospectively in 442 immunocompromised and 126 nonimmunocompromised control subjects. CMV culture in BAL fluid was performed by shell vial assay and immunostaining using three monoclonal anti-CMV antibodies.

Results: The incidence of culture results positive for CMV in the BAL fluid varied from 20 to 30% in HIV-positive patients, in patients following stem cell or renal transplantation, and in patients with autoimmune disease or lung fibrosis treated with immunosuppressive agents. CMV was cultured from 4.4% of BALs in patients treated with high-dose chemotherapy and from 2.4% of control subjects. CMV disease developed in 37 patients; in 18 of these patients, CMV pneumonitis was present. The results of CMV immunostaining were positive in a total of 22 BALs, all in patients with CMV disease. The sensitivity, specificity, and positive and negative predictive values of positive CMV immunostaining results for the diagnosis of CMV pneumonitis were 88.9%, 98.6%, 72.7%, and 99.5%, respectively.

Conclusion: The incidence of pulmonary CMV infection is similar in different groups of immunocompromised patients except for patients following high-dose chemotherapy. CMV immunostaining in the BAL fluid is a very helpful method to diagnose CMV pneumonitis in these patients.

Key Words: BAL • cytomegalovirus infection • cytomegalovirus immunostaining




This article has been cited by other articles:


Home page
ChestHome page
D. Stolz, A. Stulz, B. Muller, A. Gratwohl, and M. Tamm
BAL Neutrophils, Serum Procalcitonin, and C-Reactive Protein To Predict Bacterial Infection in the Immunocompromised Host
Chest, August 1, 2007; 132(2): 504 - 514.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Roentgenol.Home page
T. Franquet, S. Rodriguez, R. Martino, A. Gimenez, T. Salinas, and A. Hidalgo
Thin-Section CT Findings in Hematopoietic Stem Cell Transplantation Recipients with Respiratory Virus Pneumonia
Am. J. Roentgenol., October 1, 2006; 187(4): 1085 - 1090.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
L. Joos and M. Tamm
Breakdown of Pulmonary Host Defense in the Immunocompromised Host: Cancer Chemotherapy
Proceedings of the ATS, December 1, 2005; 2(5): 445 - 448.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
C. Tueller, P. N. Chhajed, C. Buitrago-Tellez, R. Frei, M. Frey, and M. Tamm
Value of smear and PCR in bronchoalveolar lavage fluid in culture positive pulmonary tuberculosis
Eur. Respir. J., November 1, 2005; 26(5): 767 - 772.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
M W Beresford, A G Cleary, J A Sills, J Couriel, and J E Davidson
Cardio-pulmonary involvement in juvenile systemic lupus erythematosus
Lupus, February 1, 2005; 14(2): 152 - 158.
[Abstract] [PDF]


Home page
J. Clin. Microbiol.Home page
R. F. Chemaly, B. Yen-Lieberman, E. A. Castilla, A. Reilly, S. Arrigain, C. Farver, R. K. Avery, S. M. Gordon, and G. W. Procop
Correlation between Viral Loads of Cytomegalovirus in Blood and Bronchoalveolar Lavage Specimens from Lung Transplant Recipients Determined by Histology and Immunohistochemistry
J. Clin. Microbiol., May 1, 2004; 42(5): 2168 - 2172.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G.-C. Chang, C.-L. Wu, S.-H. Pan, T.-Y. Yang, C.-S. Chin, Y.-C. Yang, and C.-D. Chiang
The Diagnosis of Pneumonia in Renal Transplant Recipients Using Invasive and Noninvasive Procedures
Chest, February 1, 2004; 125(2): 541 - 547.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
A T Jones, R M Du Bois, and A U Wells
The pulmonary physician in critical care * Illustrative case 2: Interstitial lung disease
Thorax, April 1, 2003; 58(4): 361 - 364.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American College of Chest Physicians.